NDA 209184 · Merz
Inbrija
Levodopa · Inhalation · Aromatic Amino Acid
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Dec 21, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
489
127 Phase 3, 26 recruiting
FAERS reports
12,511
6,194 serious, 1,389 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 20, 2026.
INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is an aromatic amino acid indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa ( 1 )
Mechanism: Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- INBRIJA · LEVODOPA 42MG · POWDER, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Levodopa" as an intervention, any sponsor and status, largest first.
- Diagnosis of PheochromocytomaRecruiting
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00004847 · 3,000 participants (planned) · Start Mar 22, 2000 · Primary completion Nov 30, 2048
Drug: ([18F]-DOPA); ([18F]-6F-DA) · For: Pheochromocytoma; Endocrine Disease; Endocrine Diseases
Sites: Bethesda, Maryland
- An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018Pivotal-lookingCompleted
Kyowa Kirin, Inc.Industry
NCT00199368 · 1,100 participants · Start Oct 2004 · Primary completion Mar 2007
Drug: Istradefylline ( KW-6002) · For: Parkinson's Disease
Sites: Princeton, New Jersey
- A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsPivotal-lookingTerminated
Eisai Inc.Eisai
NCT00360412 · 997 participants · Start Oct 2006 · Primary completion Apr 2008
Drug: E2007 · For: Parkinson's Disease
Sites: Marburg, Germany
- Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsPivotal-lookingCompleted
Eisai Inc.Eisai
NCT00368108 · 752 participants · Start Aug 2006 · Primary completion Jan 2008
Drug: 2 mg perampanel; 4 mg perampanel and 1 more · For: Parkinson's Disease
Sites: Birmingham, Alabama; Huntsville, Alabama; Peoria, Arizona · 114 sites in all
- Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa TherapyPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00099268 · 747 participants · Start Sep 2004 · Primary completion Nov 2008
Drug: Carbidopa/levodopa/entacapone; Immediate release carbidopa/levodopa · For: Parkinson's Disease
Sites: Birmingham, Alabama; Scottsdale, Arizona; La Jolla, California · 73 sites in all
- Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsPivotal-lookingTerminated
Eisai LimitedEisai
NCT00360308 · 723 participants · Start Nov 2006 · Primary completion Apr 2008
Drug: Placebo; E2007 and 1 more · For: Parkinson's Disease
Sites: Toulouse, France
- The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsPivotal-lookingCompleted
Eisai LimitedEisai
NCT00286897 · 702 participants · Start Feb 2006 · Primary completion Jun 2007
Drug: E2007 · For: Parkinson's Disease
Sites: Innsbruck, Austria; Vienna, Austria; Brussels, Belgium · 118 sites in all
- Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's DiseasePivotal-lookingCompleted
Newron Pharmaceuticals SPAIndustry
NCT01187966 · 669 participants · Start Jan 2007 · Primary completion Oct 2008
Drug: Safinamide; Safinamide and 1 more · For: Parkinson's Disease
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- cough2,350
- drug ineffective1,474
- parkinson^s disease1,081
- condition aggravated818
- dyskinesia785
- death733
- fall732
- device issue721
- hallucination674
- product residue present571
- tremor554
- device difficult to use523
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 36 |
| 2005 | 38 |
| 2006 | 65 |
| 2007 | 69 |
| 2008 | 104 |
| 2009 | 93 |
| 2010 | 120 |
| 2011 | 109 |
| 2012 | 116 |
| 2013 | 147 |
| 2014 | 200 |
| 2015 | 273 |
| 2016 | 259 |
| 2017 | 357 |
| 2018 | 507 |
| 2019 | 1,516 |
| 2020 | 1,885 |
| 2021 | 2,286 |
| 2022 | 1,630 |
| 2023 | 507 |
| 2024 | 531 |
| 2025 | 662 |
| 2026 | 1,001 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Inbrija (Levodopa)
2024 spending
$27.7M
Beneficiaries
2,431
8,665 claims
Per beneficiary
$11,390
$20.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $20,360,135 |
| 2021 | $25,158,886 |
| 2022 | $23,058,779 |
| 2023 | $27,040,847 |
| 2024 | $27,688,440 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.
Soileau MJ, Aldred J, Budur K, et al. · Lancet Neurol 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Levodopa and the progression of Parkinson's disease.
Fahn S, Oakes D, Shoulson I, et al. · N Engl J Med 2004 · Clinical Trial, Multicenter Study
- Levodopa Added to Stroke Rehabilitation: The ESTREL Randomized Clinical Trial.
Engelter ST, Kaufmann JE, Zietz A, et al. · JAMA 2025 · Clinical Trial, Phase III, Multicenter Study
- Novel Detection and Restorative Levodopa Treatment for Preclinical Diabetic Retinopathy.
Motz CT, Chesler KC, Allen RS, et al. · Diabetes 2020 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
Verschuur CVM, Suwijn SR, Boel JA, et al. · N Engl J Med 2019 · Equivalence Trial, Multicenter Study
- Levodopa failure in chronic manganism.
Lu CS, Huang CC, Chu NS, et al. · Neurology 1994 · Clinical Trial, Randomized Controlled Trial
Sponsor: Merz
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.